NIH R01 · 2025
Clinical Implementation of Blood Pressure Polygenic Risk Score: A Randomized Clinical Trial
Elevated blood pressure (BP) is the single greatest modifiable contributor to premature mortality globally. The development of hypertension (HTN) and associated adverse cardiovascular (CV) events is contributed by an interplay of genetic and environmental factors. We constructed a genome-wide systolic BP (SBP) polygenic risk score (PRS), assimilating the risk for elevated BP conferred by over 1 million common genetic variations. In a US cohort, we have also demonstrated that the SBP PRS predicts the risk of adverse CV events beyond traditional CV risk factors, including clinic-measured BP. However, the high genetic risk for adverse CV events may be offset by controlling traditional CV risk…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.